Skip to main content
Erschienen in: Annals of Surgical Oncology 4/2006

01.04.2006

Intraductal Papillary Mucinous Neoplasms of the Pancreas: Effect of Invasion and Pancreatic Margin Status on Recurrence and Survival

verfasst von: Chandrajit P. Raut, MD, Karen R. Cleary, MD, Gregg A. Staerkel, MD, James L. Abbruzzese, MD, Robert A. Wolff, MD, Jeffrey H. Lee, MD, Jean-Nicolas Vauthey, MD, Jeffrey E. Lee, MD, Peter W. T. Pisters, MD, Douglas B. Evans, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 4/2006

Einloggen, um Zugang zu erhalten

Abstract

Background

The natural history and prognosis for patients with intraductal papillary mucinous neoplasms (IPMN) with and without invasion remain poorly defined. This study evaluated the outcome after pancreatectomy for IPMN according to the pancreatic transection margin status and the presence or absence of invasive carcinoma.

Methods

Data from a prospective pancreatic tumor database and medical records were reviewed for all patients who underwent pancreatic resection for IPMN at our institution between July 1990 and July 2003. Surgical specimens were re-reviewed by a single pathologist.

Results

IPMN was diagnosed in 35 (26%) of 137 patients who underwent pancreatic resection for cystic neoplasms. Invasive IPMN was confirmed in 13 (37%) of 35 patients. Noninvasive IPMN was found in 22 (63%) of 35 patients; pathology re-review changed the original diagnosis from invasive to noninvasive IPMN in 6 patients. Noninvasive IPMN was found at the final pancreatic margin in eight patients; none developed recurrent disease at a median follow-up of 34 months. Recurrent disease was identified in 7 (58%) of 13 patients with invasive IPMN and in none with noninvasive IPMN. The median overall survival was 22.9 and 84.9 months in patients with invasive and noninvasive IPMN, respectively (P = .0009).

Conclusions

Distinction between invasive and noninvasive IPMN is essential in estimating prognosis and determining the need for adjuvant therapy and the frequency of follow-up surveillance. Noninvasive IPMN, even if present at the pancreatic margin, was not associated with recurrent disease. In contrast, invasive IPMN was associated with early recurrence and short survival.
Literatur
1.
Zurück zum Zitat Adsay NV. Intraductal papillary mucinous neoplasms of the pancreas: pathology and molecular genetics. J Gastrointest Surg 2002; 6:656–9CrossRefPubMed Adsay NV. Intraductal papillary mucinous neoplasms of the pancreas: pathology and molecular genetics. J Gastrointest Surg 2002; 6:656–9CrossRefPubMed
2.
Zurück zum Zitat Longnecker DS, Adler G, Hruban RH, Kloppel G. Intraductal papillary-mucinous neoplasms of the pancreas. In: Hamilton SR, Aaltonen LA, eds. World Health Organization Classification of Tumours: Tumours of the Digestive System. Lyon, France: IARC Press, 2000; 237–240 Longnecker DS, Adler G, Hruban RH, Kloppel G. Intraductal papillary-mucinous neoplasms of the pancreas. In: Hamilton SR, Aaltonen LA, eds. World Health Organization Classification of Tumours: Tumours of the Digestive System. Lyon, France: IARC Press, 2000; 237–240
3.
Zurück zum Zitat Agostini S, Choux R, Payan MJ, et al. Mucinous pancreatic duct ectasia in the body of the pancreas. Radiology 1989; 170(3 Pt 1):815–6PubMed Agostini S, Choux R, Payan MJ, et al. Mucinous pancreatic duct ectasia in the body of the pancreas. Radiology 1989; 170(3 Pt 1):815–6PubMed
4.
Zurück zum Zitat Farrell JJ, Brugge WR. Intraductal papillary mucinous tumor of the pancreas. Gastrointest Endosc 2002; 55:701–14CrossRefPubMed Farrell JJ, Brugge WR. Intraductal papillary mucinous tumor of the pancreas. Gastrointest Endosc 2002; 55:701–14CrossRefPubMed
5.
Zurück zum Zitat Nickl NJ, Lawson JM, Cotton PB. Mucinous pancreatic tumors: ERCP findings. Gastrointest Endosc 1991; 37:133–8PubMed Nickl NJ, Lawson JM, Cotton PB. Mucinous pancreatic tumors: ERCP findings. Gastrointest Endosc 1991; 37:133–8PubMed
6.
Zurück zum Zitat Warshaw AL, Brugge WR, Lewandrowski KB, Pitman MB. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-2003. A 75-year-old man with a cystic lesion of the pancreas. N Engl J Med 2003; 349:1954–61CrossRefPubMed Warshaw AL, Brugge WR, Lewandrowski KB, Pitman MB. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-2003. A 75-year-old man with a cystic lesion of the pancreas. N Engl J Med 2003; 349:1954–61CrossRefPubMed
7.
Zurück zum Zitat McDonald JM, Williard W, Mais D, Beitler A. The incidence of intraductal papillary mucinous tumors of the pancreas (1). Curr Surg 2000; 57:610–4PubMed McDonald JM, Williard W, Mais D, Beitler A. The incidence of intraductal papillary mucinous tumors of the pancreas (1). Curr Surg 2000; 57:610–4PubMed
8.
Zurück zum Zitat Sohn TA, Yeo CJ, Cameron JL, et al. Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity. Ann Surg 2001; 234:313–21; discussion 321–2CrossRefPubMed Sohn TA, Yeo CJ, Cameron JL, et al. Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity. Ann Surg 2001; 234:313–21; discussion 321–2CrossRefPubMed
9.
Zurück zum Zitat Hruban RH, Petersen GM, Ha PK, Kern SE. Genetics of pancreatic cancer. From genes to families. Surg Oncol Clin North Am 1998; 7:1–23 Hruban RH, Petersen GM, Ha PK, Kern SE. Genetics of pancreatic cancer. From genes to families. Surg Oncol Clin North Am 1998; 7:1–23
10.
Zurück zum Zitat Iacobuzio-Donahue CA, Klimstra DS, Adsay NV, et al. Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas. Am J Pathol 2000; 157:755–61PubMed Iacobuzio-Donahue CA, Klimstra DS, Adsay NV, et al. Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas. Am J Pathol 2000; 157:755–61PubMed
11.
Zurück zum Zitat Sato N, Rosty C, Jansen M, et al. STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. Am J Pathol 2001; 159:2017–22PubMed Sato N, Rosty C, Jansen M, et al. STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. Am J Pathol 2001; 159:2017–22PubMed
12.
Zurück zum Zitat Kokawa A, Kondo H, Gotoda T, et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer 2001; 91:333–8CrossRefPubMed Kokawa A, Kondo H, Gotoda T, et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer 2001; 91:333–8CrossRefPubMed
13.
Zurück zum Zitat Doi R, Fujimoto K, Wada M, Imamura M. Surgical management of intraductal papillary mucinous tumor of the pancreas. Surgery 2002; 132:80–5CrossRefPubMed Doi R, Fujimoto K, Wada M, Imamura M. Surgical management of intraductal papillary mucinous tumor of the pancreas. Surgery 2002; 132:80–5CrossRefPubMed
14.
Zurück zum Zitat Kimura W, Sasahira N, Yoshikawa T, et al. Duct-ectatic type of mucin producing tumor of the pancreas—new concept of pancreatic neoplasia. Hepatogastroenterology 1996; 43:692–709PubMed Kimura W, Sasahira N, Yoshikawa T, et al. Duct-ectatic type of mucin producing tumor of the pancreas—new concept of pancreatic neoplasia. Hepatogastroenterology 1996; 43:692–709PubMed
15.
Zurück zum Zitat Sugiyama M, Atomi Y, Kuroda A. Two types of mucin-producing cystic tumors of the pancreas: diagnosis and treatment. Surgery 1997; 122:617–25CrossRefPubMed Sugiyama M, Atomi Y, Kuroda A. Two types of mucin-producing cystic tumors of the pancreas: diagnosis and treatment. Surgery 1997; 122:617–25CrossRefPubMed
16.
Zurück zum Zitat Maire F, Hammel P, Terris B, et al. Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma. Gut 2002; 51:717–22PubMed Maire F, Hammel P, Terris B, et al. Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma. Gut 2002; 51:717–22PubMed
17.
Zurück zum Zitat Fukushima N, Mukai K. Pancreatic neoplasms with abundant mucus production: emphasis on intraductal papillary-mucinous tumors and mucinous cystic tumors. Adv Anat Pathol 1999; 6:65–77PubMed Fukushima N, Mukai K. Pancreatic neoplasms with abundant mucus production: emphasis on intraductal papillary-mucinous tumors and mucinous cystic tumors. Adv Anat Pathol 1999; 6:65–77PubMed
18.
Zurück zum Zitat Greene FL, Page DL, Fleming ID, et al., eds. Exocrine pancreas. In: AJCC Cancer Staging Manual. Chicago: Springer-Verlag, 2002; 157–64 Greene FL, Page DL, Fleming ID, et al., eds. Exocrine pancreas. In: AJCC Cancer Staging Manual. Chicago: Springer-Verlag, 2002; 157–64
19.
Zurück zum Zitat Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457–81 Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457–81
20.
Zurück zum Zitat Ohhashi K, Murakami Y, Takekoshi T. Four cases of mucin producing cancer of the pancreas on specific findings of the papilla of Vater. Prog Dig Endosc 1982; 20:348–51 Ohhashi K, Murakami Y, Takekoshi T. Four cases of mucin producing cancer of the pancreas on specific findings of the papilla of Vater. Prog Dig Endosc 1982; 20:348–51
21.
Zurück zum Zitat Kloppel G, Solcia E, Longnecker DS, et al. Histologic Typing of Tumors of the Exocrine Pancreas. World Health Organization International Histologic Classification of Tumors. Geneva: Springer, 1996 Kloppel G, Solcia E, Longnecker DS, et al. Histologic Typing of Tumors of the Exocrine Pancreas. World Health Organization International Histologic Classification of Tumors. Geneva: Springer, 1996
22.
Zurück zum Zitat Adsay NV. The “new kid on the block”: intraductal papillary mucinous neoplasms of the pancreas—current concepts and controversies. Surgery 2003; 133:459–63CrossRefPubMed Adsay NV. The “new kid on the block”: intraductal papillary mucinous neoplasms of the pancreas—current concepts and controversies. Surgery 2003; 133:459–63CrossRefPubMed
23.
Zurück zum Zitat Kitagawa Y, Unger TA, Taylor S, et al. Mucus is a predictor of better prognosis and survival in patients with intraductal papillary mucinous tumor of the pancreas. J Gastrointest Surg 2003; 7:12–8; discussion 18–9CrossRefPubMed Kitagawa Y, Unger TA, Taylor S, et al. Mucus is a predictor of better prognosis and survival in patients with intraductal papillary mucinous tumor of the pancreas. J Gastrointest Surg 2003; 7:12–8; discussion 18–9CrossRefPubMed
24.
Zurück zum Zitat Rivera JA, Fernandez-del Castillo C, Pins M, et al. Pancreatic mucinous ductal ectasia and intraductal papillary neoplasms. A single malignant clinicopathologic entity. Ann Surg 1997; 225:637–44; discussion 644–6CrossRefPubMed Rivera JA, Fernandez-del Castillo C, Pins M, et al. Pancreatic mucinous ductal ectasia and intraductal papillary neoplasms. A single malignant clinicopathologic entity. Ann Surg 1997; 225:637–44; discussion 644–6CrossRefPubMed
25.
Zurück zum Zitat Navarro F, Michel J, Bauret P, et al. Management of intraductal papillary mucinous tumours of the pancreas. Eur J Surg 1999; 165:43–8PubMed Navarro F, Michel J, Bauret P, et al. Management of intraductal papillary mucinous tumours of the pancreas. Eur J Surg 1999; 165:43–8PubMed
26.
Zurück zum Zitat Kaserer K, Schmaus J, Bethge U, et al. Staining patterns of p53 immunohistochemistry and their biological significance in colorectal cancer. J Pathol 2000; 190:450–6CrossRefPubMed Kaserer K, Schmaus J, Bethge U, et al. Staining patterns of p53 immunohistochemistry and their biological significance in colorectal cancer. J Pathol 2000; 190:450–6CrossRefPubMed
27.
Zurück zum Zitat Obara T, Maguchi H, Saitoh Y, et al. Mucin-producing tumor of the pancreas: surgery or follow-up? Nippon Shokakibyo Gakkai Zasshi 1994; 91:66–74PubMed Obara T, Maguchi H, Saitoh Y, et al. Mucin-producing tumor of the pancreas: surgery or follow-up? Nippon Shokakibyo Gakkai Zasshi 1994; 91:66–74PubMed
28.
Zurück zum Zitat Traverso LW, Peralta EA, Ryan JA Jr, Kozarek RA. Intraductal neoplasms of the pancreas. Am J Surg 1998; 175:426–32PubMed Traverso LW, Peralta EA, Ryan JA Jr, Kozarek RA. Intraductal neoplasms of the pancreas. Am J Surg 1998; 175:426–32PubMed
29.
Zurück zum Zitat Jang J-Y, Kim S-W, Ahn YJ, et al. Multicenter analysis of clinicopathologic features of intraductal papillary mucinous tumor of the pancreas: is it possible to predict the malignancy before surgery? Ann Surg Oncol 2005; 12:124–32CrossRefPubMed Jang J-Y, Kim S-W, Ahn YJ, et al. Multicenter analysis of clinicopathologic features of intraductal papillary mucinous tumor of the pancreas: is it possible to predict the malignancy before surgery? Ann Surg Oncol 2005; 12:124–32CrossRefPubMed
30.
Zurück zum Zitat Raut CP, Grau AM, Staerkel GA, et al. Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration in patients with presumed pancreatic cancer. J Gastrointest Surg 2003; 7:118–28CrossRefPubMed Raut CP, Grau AM, Staerkel GA, et al. Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration in patients with presumed pancreatic cancer. J Gastrointest Surg 2003; 7:118–28CrossRefPubMed
31.
Zurück zum Zitat Nakagohri T, Asano T, Kenmochi T, et al. Long-term surgical outcome of noninvasive and minimally invasive intraductal papillary mucinous adenocarcinoma of the pancreas. World J Surg 2002; 26:1166–9CrossRefPubMed Nakagohri T, Asano T, Kenmochi T, et al. Long-term surgical outcome of noninvasive and minimally invasive intraductal papillary mucinous adenocarcinoma of the pancreas. World J Surg 2002; 26:1166–9CrossRefPubMed
32.
Zurück zum Zitat Zamora C, Sahel J, Cantu DG, et al. Intraductal papillary or mucinous tumors (IPMT) of the pancreas: report of a case series and review of the literature. Am J Gastroenterol 2001; 96:1441–7CrossRefPubMed Zamora C, Sahel J, Cantu DG, et al. Intraductal papillary or mucinous tumors (IPMT) of the pancreas: report of a case series and review of the literature. Am J Gastroenterol 2001; 96:1441–7CrossRefPubMed
33.
Zurück zum Zitat Breslin TM, Hess KR, Harbison DB, et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 2001; 8:123–32PubMed Breslin TM, Hess KR, Harbison DB, et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 2001; 8:123–32PubMed
Metadaten
Titel
Intraductal Papillary Mucinous Neoplasms of the Pancreas: Effect of Invasion and Pancreatic Margin Status on Recurrence and Survival
verfasst von
Chandrajit P. Raut, MD
Karen R. Cleary, MD
Gregg A. Staerkel, MD
James L. Abbruzzese, MD
Robert A. Wolff, MD
Jeffrey H. Lee, MD
Jean-Nicolas Vauthey, MD
Jeffrey E. Lee, MD
Peter W. T. Pisters, MD
Douglas B. Evans, MD
Publikationsdatum
01.04.2006
Erschienen in
Annals of Surgical Oncology / Ausgabe 4/2006
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/ASO.2006.05.002

Weitere Artikel der Ausgabe 4/2006

Annals of Surgical Oncology 4/2006 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.